Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Website: bioatla.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -100.1% (LTM)

Entry Point: Share price is 100.3% higher than minimum and 93.1% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: BCAB
Share price, USD:  (0.0%)0.5342
year average price 0.5202  


year start price 0.5547 2025-01-08

min close price 0.2667 2025-04-08

max close price 1.2200 2025-11-18

current price 0.5342 2026-01-07
Common stocks: 37 413 902

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 20
Net Debt ($m): -214
EV (Enterprise Value): -194
Price to Book: -0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-31globenewswire.com

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

2025-11-21globenewswire.com

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

2025-11-13seekingalpha.com

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

2025-08-09seekingalpha.com

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

2025-01-02zacks.com

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

2024-11-09seekingalpha.com

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

2024-10-08seekingalpha.com

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

2024-10-07seekingalpha.com

BioAtla: Numerous Catalysts Coming In Q4

2024-10-04globenewswire.com

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

2024-10-01finbold.com

Michael Burry buys 634,000 shares of this $1 penny stock
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-07 2024-11-07 2024-08-08 2024-05-14 2024-03-26 2023-11-07 2023-08-01 2023-05-11 2023-03-23 2022-11-04
acceptedDate 2025-11-13 17:00:55 2025-08-07 17:01:11 2024-11-07 17:05:19 2024-08-08 17:01:23 2024-05-14 17:01:36 2024-03-26 17:05:34 2023-11-07 17:05:27 2023-08-01 17:00:57 2023-05-11 17:00:48 2023-03-23 17:06:25 2022-11-04 06:05:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 11M 0 0 2M 0 0 0 0 0
costOfRevenue 56 000 567 000 0 229 000 240 000 368 000 270 000 290 000 0 0 0
grossProfit -56 000 -567 000 11M -229 000 -240 000 1M -270 000 -290 000 0 0 0
grossProfitRatio 0 0 1 0 0 0.784 0 0 0 0 0
researchAndDevelopmentExpenses 10M 14M 16M 16M 19M 23M 28M 31M 22M 22M 20M
generalAndAdministrativeExpenses 0 5M 6M 6M 6M 6M 7M 6M 7M 7M 6M
sellingAndMarketingExpenses 0 0 0 -229 000 -240 000 -368 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 5M 6M 6M 5M 5M 7M 6M 7M 7M 6M
otherExpenses 0 -567 000 0 229 000 0 -27 000 -39 000 -11 000 -10000 -30 000 0
operatingExpenses 14M 18M 22M 22M 24M 28M 35M 37M 29M 29M 26M
costAndExpenses 14M 19M 22M 22M 24M 29M 35M 37M 29M 29M 26M
interestIncome 133 000 233 000 692 000 900 000 1M 2M 2M 1M 1M 1M 370 000
interestExpense 0 0 0 0 0 1M 0 0 -1M -516 000 370 000
depreciationAndAmortization 56 000 115 000 228 000 229 000 240 000 368 000 270 000 290 000 293 000 1M 700 000
ebitda -16M -19M -11M -22M -24M -28M -35M -37M -29M -28M -25M
ebitdaratio 0 0 -1.004 0 0 -16.511 0 0 0 0 0
operatingIncome -14M -19M -11M -22M -24M -29M -35M -37M -29M -29M -26M
operatingIncomeRatio 0 0 -1.025 0 0 -16.727 0 0 0 0 0
totalOtherIncomeExpensesNet -2M -64 000 684 000 900 000 1M 2M -39 000 -11 000 1M 1M 400 000
incomeBeforeTax -16M -19M -11M -21M -23M -27M -33M -36M -27M -28M -26M
incomeBeforeTaxRatio 0 0 -0.962 0 0 -15.783 0 0 0 0 0
incomeTaxExpense 0 0 0 0 196 724 5M -2M -1M -1M 218 000 -370 000
netIncome -16M -19M -11M -21M -23M -27M -33M -36M -26M -28M -25M
netIncomeRatio 0 0 -0.962 0 0 -15.783 0 0 0 0 0
eps -0.27 -0.32 -0.22 -0.44 -0.48 -0.56 -0.7 -0.75 -0.55 -0.58 -0.68
epsdiluted -0.27 -0.32 -0.22 -0.44 -0.48 -0.56 -0.7 -0.75 -0.55 -0.58 -0.68
weightedAverageShsOut 59M 59M 48M 48M 48M 48M 48M 48M 48M 48M 38M
weightedAverageShsOutDil 59M 59M 48M 48M 48M 48M 48M 48M 48M 48M 38M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-07 2024-11-07 2024-08-08 2024-05-14 2024-03-26 2023-11-07 2023-08-01 2023-05-11 2023-03-23 2022-11-04
acceptedDate 2025-11-13 17:00:55 2025-08-07 17:01:11 2024-11-07 17:05:19 2024-08-08 17:01:23 2024-05-14 17:01:36 2024-03-26 17:05:34 2023-11-07 17:05:27 2023-08-01 17:00:57 2023-05-11 17:00:48 2023-03-23 17:06:25 2022-11-04 06:05:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 8M 18M 57M 62M 81M 111M 141M 169M 193M 216M 178M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 8M 18M 57M 62M 81M 111M 141M 169M 193M 216M 178M
netReceivables 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 1M 2M 4M 5M 6M 5M 6M 687 000 469 000 539 000 519 000
totalCurrentAssets 10M 21M 61M 66M 86M 116M 141M 175M 200M 220M 183M
propertyPlantEquipmentNet 6M 6M 0 2M 3M 3M 4M 4M 5M 5M 6M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 163 000 163 000 2M 0 154 000 153 999 6M 154 000 154 000 154 000 154 000
totalNonCurrentAssets 6M 7M 2M 2M 3M 3M 10M 4M 5M 5M 6M
otherAssets 0 0 0 1 0 1 0 0 0 0 0
totalAssets 16M 27M 62M 69M 89M 120M 151M 180M 205M 226M 189M
accountPayables 0 5M 0 1M 3M 4M 6M 3M 8M 4M 4M
shortTermDebt 1M 805 000 1M 3M 2M 2M 2M 2M 2M 2M 1M
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 -6M -3M 0 0 0
otherCurrentLiabilities 17M 11M 18M 13M 14M 23M 34M 32M 17M 17M 19M
totalCurrentLiabilities 18M 17M 19M 17M 19M 28M 36M 34M 26M 23M 24M
longTermDebt 5M 5M 0 0 415 000 836 000 1M 2M 2M 2M 3M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 24M 22M 20M 20M 20M 20M 20M 20M 20M 20M 17M
totalNonCurrentLiabilities 29M 27M 20M 20M 20M 21M 21M 21M 22M 22M 23M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0
capitalLeaseObligations 0 6M 1M 2M 415 000 836 000 3M 3M 4M 4M 4M
totalLiabilities 47M 44M 39M 37M 39M 49M 57M 55M 48M 45M 46M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 6000 6000 5000 5000 5000 5000 5000 5000 5000 5000 4000
retainedEarnings -536M -520M -471M -461M -439M -416M -389M -356M -320M -293M -265M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 -0 0 0 0 0 0
othertotalStockholdersEquity 505M 503M 494M 492M 489M 487M 484M 481M 477M 473M 408M
totalStockholdersEquity -31M -17M 23M 31M 50M 71M 95M 125M 156M 180M 143M
totalEquity -31M -17M 23M 31M 50M 71M 95M 125M 156M 180M 143M
totalLiabilitiesAndStockholdersEquity 16M 27M 62M 69M 89M 120M 151M 180M 205M 226M 189M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 16M 27M 62M 69M 89M 120M 151M 180M 205M 226M 189M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0
totalDebt 6M 6M 1M 2M 2M 2M 3M 3M 4M 4M 4M
netDebt -2M -12M -55M -60M -79M -109M -138M -165M -189M -212M -174M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB BCAB
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-07 2024-11-07 2024-08-08 2024-05-14 2024-03-26 2023-11-07 2023-08-01 2023-05-11 2023-03-23 2022-11-04
acceptedDate 2025-11-13 17:00:55 2025-08-07 17:01:11 2024-11-07 17:05:19 2024-08-08 17:01:23 2024-05-14 17:01:36 2024-03-26 17:05:34 2023-11-07 17:05:27 2023-08-01 17:00:57 2023-05-11 17:00:48 2023-03-23 17:06:25 2022-11-04 06:05:23
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -16M -19M -11M -21M -23M -27M -33M -36M -27M -28M -26M
depreciationAndAmortization 56 000 115 000 228 000 229 000 240 000 368 000 270 000 290 000 293 000 298 000 300 000
deferredIncomeTax 0 0 0 0 0 -11M -30M -32M 0 0 0
stockBasedCompensation 0 0 2M 2M 2M 3M 4M 4M 4M 4M 4M
changeInWorkingCapital 1M 3M 11M -846 000 -10M -6M 2M 8M 899 000 -610 000 -2M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 0 421 000 640 000 -2M -9M -7M 2M 7M 3M 2M -2M
otherWorkingCapital 1M 2M 10M 1M -1M 1M 235 000 269 000 -2M -2M -422 000
otherNonCashItems 4M 2M -8M 5M 12M 11M 30M 32M 0 7000 0
netCashProvidedByOperatingActivities -10M -14M -5M -19M -31M -30M -27M -24M -23M -24M -24M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 -8000 -25 000 -15 000 -50 000 -31 000 -58 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 0 -8000 -25 000 -15 000 -50 000 -31 000 -58 000
debtRepayment 0 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 47 000 -244 000 244 000 0 149 000 27 000 54 000 0 62M 0
commonStockRepurchased -6000 0 13 244 000 -13 -30 14 000 173 000 0 289 000 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 -5000 -14 000 225 000 -13 000 149 -82 000 -112 000 -116 000 -206 000 -96 000
netCashUsedProvidedByFinancingActivities -6000 42 000 -14 000 225 000 -13 000 119 -41 000 115 000 -116 000 62M -96 000
effectOfForexChangesOnCash 0 0 0 0 0 10M -2M -8M 0 0 0
netChangeInCash -10M -14M -5M -19M -31M -30M -27M -24M -23M 37M -24M
cashAtEndOfPeriod 8M 18M 57M 62M 81M 111M 141M 169M 193M 216M 178M
cashAtBeginningOfPeriod 18M 32M 62M 81M 111M 141M 169M 193M 216M 178M 202M
operatingCashFlow -10M -14M -5M -19M -31M -30M -27M -24M -23M -24M -24M
capitalExpenditure 0 14M 0 0 0 -8000 -25 000 -15 000 -50 000 -31 000 -58 000
freeCashFlow -10M 0 -5M -19M -31M -30M -27M -24M -23M -24M -24M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-13 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-03-27 ET (fiscal 2024 q4)
2024 q3
2024-11-09 ET (fiscal 2024 q3)
2024 q2
2024-08-11 ET (fiscal 2024 q2)
2024 q1
2024-05-14 ET (fiscal 2024 q1)
2023 q4
2024-03-26 ET (fiscal 2023 q4)
2023 q3
2023-11-12 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-23 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-13 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-13 17:00 ET
BioAtla, Inc. reported for 2025 q3
SEC form 8
2025-11-13 16:06 ET
BioAtla, Inc. reported for 2025 q3
SEC form 8
2025-11-13 16:06 ET
BioAtla, Inc. published news for 2025 q3
SEC form 10
2025-08-07 21:01 ET
BioAtla, Inc. reported for 2025 q2
SEC form 8
2025-08-07 20:06 ET
BioAtla, Inc. published news for 2025 q2
SEC form 8
2025-08-07 20:06 ET
BioAtla, Inc. reported for 2025 q2
SEC form 10
2025-05-06 21:01 ET
BioAtla, Inc. reported for 2025 q1
SEC form 8
2025-05-06 20:01 ET
BioAtla, Inc. published news for 2025 q1
SEC form 8
2025-05-06 20:01 ET
BioAtla, Inc. reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
BioAtla, Inc. reported for 2025 q1
SEC form 10
2025-03-28 00:00 ET
BioAtla, Inc. reported for 2024 q4
SEC form 10
2025-03-27 21:44 ET
BioAtla, Inc. reported for 2024 q4
SEC form 8
2025-03-27 16:09 ET
BioAtla, Inc. reported for 2024 q4
SEC form 8
2025-03-27 16:09 ET
BioAtla, Inc. published news for 2024 q4
SEC form 10
2024-11-07 17:05 ET
BioAtla, Inc. reported for 2024 q3
SEC form 8
2024-11-07 16:05 ET
BioAtla, Inc. published news for 2024 q3
SEC form 8
2024-11-07 16:05 ET
BioAtla, Inc. reported for 2024 q3
SEC form 10
2024-08-08 17:01 ET
BioAtla, Inc. reported for 2024 q2
SEC form 8
2024-08-08 16:05 ET
BioAtla, Inc. reported for 2024 q2
SEC form 8
2024-08-08 16:05 ET
BioAtla, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
BioAtla, Inc. reported for 2024 q2
SEC form 10
2024-05-14 17:01 ET
BioAtla, Inc. reported for 2024 q1
SEC form 8
2024-05-14 16:05 ET
BioAtla, Inc. reported for 2024 q1
SEC form 8
2024-05-14 16:05 ET
BioAtla, Inc. published news for 2024 q1
SEC form 10
2024-05-14 00:00 ET
BioAtla, Inc. reported for 2024 q1
SEC form 10
2024-03-26 17:05 ET
BioAtla, Inc. reported for 2023 q4
SEC form 8
2024-03-26 16:01 ET
BioAtla, Inc. published news for 2023 q4
SEC form 8
2024-03-26 16:01 ET
BioAtla, Inc. reported for 2023 q4
SEC form 10
2024-03-26 00:00 ET
BioAtla, Inc. reported for 2023 q4
SEC form 10
2023-11-07 17:05 ET
BioAtla, Inc. reported for 2023 q3
SEC form 8
2023-11-07 16:02 ET
BioAtla, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
BioAtla, Inc. reported for 2023 q3
SEC form 10
2023-08-01 17:00 ET
BioAtla, Inc. reported for 2023 q2
SEC form 6
2023-08-01 16:02 ET
BioAtla, Inc. reported for 2023 q2
SEC form 8
2023-08-01 00:00 ET
BioAtla, Inc. reported for 2023 q2
SEC form 10
2023-08-01 00:00 ET
BioAtla, Inc. reported for 2023 q2
SEC form 6
2023-06-14 17:01 ET
BioAtla, Inc. published news for 2023 q1
SEC form 10
2023-05-11 17:00 ET
BioAtla, Inc. reported for 2023 q1
SEC form 6
2023-05-11 16:06 ET
BioAtla, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
BioAtla, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
BioAtla, Inc. reported for 2023 q1
SEC form 6
2023-04-24 17:12 ET
BioAtla, Inc. published news for 2023 q1
SEC form 10
2023-03-23 17:06 ET
BioAtla, Inc. reported for 2022 q4
SEC form 6
2023-03-23 16:02 ET
BioAtla, Inc. reported for 2022 q4
SEC form 8
2023-03-23 00:00 ET
BioAtla, Inc. reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
BioAtla, Inc. reported for 2022 q4
SEC form 10
2022-11-04 00:00 ET
BioAtla, Inc. reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
BioAtla, Inc. reported for 2022 q3
SEC form 8
2022-08-09 00:00 ET
BioAtla, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
BioAtla, Inc. reported for 2022 q2
SEC form 10
2022-05-05 00:00 ET
BioAtla, Inc. reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
BioAtla, Inc. reported for 2022 q1
SEC form 10
2022-02-28 00:00 ET
BioAtla, Inc. published news for 2021 q4
SEC form 10
2021-11-15 00:00 ET
BioAtla, Inc. published news for 2021 q3
SEC form 10
2021-08-13 00:00 ET
BioAtla, Inc. published news for 2021 q2
SEC form 10
2021-05-12 00:00 ET
BioAtla, Inc. published news for 2021 q1